COMPOSITION FOR STIMULATING DENDRITIC CELL MATURATION, CONTAINING HYBRID PROTEIN RV2299C/ESAT-6 Russian patent published in 2020 - IPC C12N5/784 C07K14/35 A61K38/16 A61P37/04 

Abstract RU 2733886 C2

FIELD: biotechnology.

SUBSTANCE: present invention relates to hybrid immunomodulatory proteins, and can be used for induction of dendritic cell maturation (DC) and immunity enhancement. Rv2299c/ESAT-6 hybrid protein consists of ESAT-6 protein fused with Rv2299c, and is capable of inducing aging of the DC. Method for induction of immature DC maturation involves differentiation of mononuclear cells isolated from blood into immature DCs; and treating said immature DCs with Rv2299c/ESAT-6 hybrid protein to provide maturation of said immature DCs to mature DCs. Said fusion protein Rv2299c/ESAT-6 is used in concentration of 1 mcg/ml to 20 mcg/ml.

EFFECT: invention provides preparing a nontoxic immunomodulator for inducing an immune response by stimulating DC differentiation.

9 cl, 12 dwg, 11 ex

Similar patents RU2733886C2

Title Year Author Number
COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX CONTAINING A CELL-PENETRATING PEPTIDE, A CARGO MOLECULE, AND A TLR PEPTIDE AGONIST, FOR APPLICATION IN MEDICINE 2017
  • Derouazi Madiha
  • Belnoue Elodie
RU2769314C1
RECOMBINANT STRAIN OF INFLUENZA VIRUS A/PR8-NS124-TB10_4-2A-HSPX AND METHOD FOR SPECIFIC PREVENTION OF PULMONARY TUBERCULOSIS USING MUCOSAL VACCINE BASED THEREON 2019
  • Stukova Marina Anatolevna
  • Vinogradova Tatyana Ivanovna
  • Zabolotnykh Nataliya Vyacheslavovna
  • Sergeeva Mariya Valerevna
  • Buzitskaya Zhanna Valerevna
RU2726106C1
COMBINATION OF IMMUNE CHECKPOINT MODULATOR AND COMPLEX CONTAINING CELL-PENETRATING PEPTIDE, CARGO MOLECULE, AND TLR PEPTIDE AGONIST FOR MEDICAL USE 2017
  • Deruazi Madikha
  • Belnu Elodi
RU2748378C2
FUSION CONSTRUCTION CONTAINING CELL PENETRATING PEPTIDE, POLYEPITOPE AND TLR PEPTIDE AGONIST, INTENDED FOR TREATMENT OF CANCER 2017
  • Derouazi Madiha
  • Belnoue Elodie
RU2807135C2
VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT 2016
  • Wucherpfennig, Kai
  • Badrinath, Soumya
RU2747296C2
COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY 2018
  • Hochrein, Hubertus
  • Lauterbach, Henning
  • Medina Echeverz, Jose
  • Habjan, Matthias
RU2795103C2
NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN 2016
  • Zheng, Yong
  • Li, Jing
  • Gololobov, Gennady
  • Zhang, Xinhua
  • Yang, Baotian
  • Tang, Zhewei
  • Li, Dong
  • Xu, Jianqing
  • Wang, Zhuozhi
RU2757316C2
MEDICINAL PRODUCT 2017
  • Miyakawa, Tomoya
  • Doi, Shun
  • Tamada, Koji
RU2759728C2
VIRUS VECTOR 2020
  • Cerullo Vincenzo
  • Capasso Cristian
  • Feola Sara
  • Tahtinen Siri
RU2799418C1
ANTIBODIES AND POLYPEPTIDES AGAINST CD127 2017
  • Puare, Nikolya
  • Mari, Karolina
  • Vankhove, Bernard
  • Tepene, Virzhini
RU2769352C2

RU 2 733 886 C2

Authors

Kim, Khva-Yung

Tsoj, Khan-Gi

Sin, Sun-Che

Dates

2020-10-07Published

2017-06-07Filed